The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Farlutal     (6S,8R,9S,10R,13S,14S,17R)- 17-ethanoyl-17...

Synonyms: Asconale, Colirest, Adgyn Medro, medroxyprogesterone, Methylhydroxyprogesterone, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Farlutal


Psychiatry related information on Farlutal


High impact information on Farlutal


Chemical compound and disease context of Farlutal


Biological context of Farlutal


Anatomical context of Farlutal


Associations of Farlutal with other chemical compounds


Gene context of Farlutal


Analytical, diagnostic and therapeutic context of Farlutal


  1. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Miyagawa, K., Rösch, J., Stanczyk, F., Hermsmeyer, K. Nat. Med. (1997) [Pubmed]
  2. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. Liang, A.P., Levenson, A.G., Layde, P.M., Shelton, J.D., Hatcher, R.A., Potts, M., Michelson, M.J. JAMA (1983) [Pubmed]
  3. Progesterone administration and progressive sleep apneas. Strohl, K.P., Hensley, M.J., Saunders, N.A., Scharf, S.M., Brown, R., Ingram, R.H. JAMA (1981) [Pubmed]
  4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E. JAMA (1998) [Pubmed]
  5. Alternative hormone replacement regimens: is there a need for further clinical trials? Welty, F.K. Curr. Opin. Lipidol. (2003) [Pubmed]
  6. Medroxyprogesterone acetate as a treatment for sexual acting out in organic brain syndrome. Cooper, A.J. The American journal of psychiatry. (1988) [Pubmed]
  7. Extreme bradycardia during sleep apnea caused by myxedema. Abouganem, D., Taylor, A.L., Donna, E., Baum, G.L. Arch. Intern. Med. (1987) [Pubmed]
  8. Treatment of sex offenders with medroxyprogesterone acetate. Gagné, P. The American journal of psychiatry. (1981) [Pubmed]
  9. Effects of alcohol ingestion on estrogens in postmenopausal women. Ginsburg, E.S., Mello, N.K., Mendelson, J.H., Barbieri, R.L., Teoh, S.K., Rothman, M., Gao, X., Sholar, J.W. JAMA (1996) [Pubmed]
  10. Inhibitory effect of medroxyprogesterone acetate on foreign body tumorigenesis in mice. Lanari, C., Molinolo, A.A., Pasqualini, C.D. J. Natl. Cancer Inst. (1986) [Pubmed]
  11. Effect of medroxyprogesterone and an aorta-derived cell growth inhibitor on B16 melanoma in mice. Eisenstein, R., Schumacher, B., Hsiao, K., Eisenstein, N., Lemke, M., Anderson, T., Harper, E. J. Natl. Cancer Inst. (1984) [Pubmed]
  12. Tamoxifen versus medroxyprogesterone acetate for metastatic breast cancer. Atkins, C.D. J. Clin. Oncol. (1994) [Pubmed]
  13. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. Nagel, G.A., Wander, H.E., Blossey, H.C. Cancer Res. (1982) [Pubmed]
  14. Hormone replacement therapy and cardiovascular disease. Rossouw, J.E. Curr. Opin. Lipidol. (1999) [Pubmed]
  15. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Civitelli, R., Pilgram, T.K., Dotson, M., Muckerman, J., Lewandowski, N., Armamento-Villareal, R., Yokoyama-Crothers, N., Kardaris, E.E., Hauser, J., Cohen, S., Hildebolt, C.F. Arch. Intern. Med. (2002) [Pubmed]
  16. Progesterone for outpatient treatment of Pickwickian syndrome. Sutton, F.D., Zwillich, C.W., Creagh, C.E., Pierson, D.J., Weil, J.V. Ann. Intern. Med. (1975) [Pubmed]
  17. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. Etienne, M.C., Milano, G., Frenay, M., Renee, N., Francois, E., Thyss, A., Schneider, M., Namer, M. J. Clin. Oncol. (1992) [Pubmed]
  18. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Sutherland, R.L., Hall, R.E., Pang, G.Y., Musgrove, E.A., Clarke, C.L. Cancer Res. (1988) [Pubmed]
  19. Population-based case-control study of ovarian cancer in Shanghai. Shu, X.O., Brinton, L.A., Gao, Y.T., Yuan, J.M. Cancer Res. (1989) [Pubmed]
  20. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Prior, J.C., Vigna, Y.M., Barr, S.I., Rexworthy, C., Lentle, B.C. Am. J. Med. (1994) [Pubmed]
  21. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Levine, R.L., Chen, S.J., Durand, J., Chen, Y.F., Oparil, S. Circulation (1996) [Pubmed]
  22. Endogenous growth factor expression in T-47D, human breast cancer cells, associated with reduced sensitivity to antiproliferative effects of progestins and antiestrogens. Murphy, L.C., Dotzlaw, H. Cancer Res. (1989) [Pubmed]
  23. Histological evaluation of in vitro responses of endometrial adenocarcinoma to progestins and their relation to progesterone receptor levels. Holinka, C.F., Deligdisch, L., Gurpide, E. Cancer Res. (1984) [Pubmed]
  24. Postmenopausal estrogen replacement: a long-term cohort study. Lafferty, F.W., Fiske, M.E. Am. J. Med. (1994) [Pubmed]
  25. Lower sphincter of the opossum esophagus in pseudopregnancy. Schulze, K., Christensen, J. Gastroenterology (1977) [Pubmed]
  26. Protective effect of medroxyprogesterone acetate plus testosterone against radiation-induced damage to the reproductive function of male rats and their offspring. Jégou, B., Velez de la Calle, J.F., Bauché, F. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  27. Effect of hormone therapy on risk of hip and knee joint replacement in the women's health initiative. Cirillo, D.J., Wallace, R.B., Wu, L., Yood, R.A. Arthritis Rheum. (2006) [Pubmed]
  28. Simultaneous measurement of progesterone and androgen receptors in human prostate: a microassay. Ekman, P., Barrack, E.R., Walsh, P.C. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  29. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. Sites, C.K., L'Hommedieu, G.D., Toth, M.J., Brochu, M., Cooper, B.C., Fairhurst, P.A. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  30. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. Birrell, S.N., Roder, D.M., Horsfall, D.J., Bentel, J.M., Tilley, W.D. J. Clin. Oncol. (1995) [Pubmed]
  31. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Kobayashi, K., Mimura, N., Fujii, H., Minami, H., Sasaki, Y., Shimada, N., Chiba, K. Clin. Cancer Res. (2000) [Pubmed]
  32. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Croston, G.E., Milan, L.B., Marschke, K.B., Reichman, M., Briggs, M.R. Endocrinology (1997) [Pubmed]
  33. Prolonged endocrine responses to medroxyprogesterone in postmenopausal women with respiratory insufficiency. Saaresranta, T., Irjala, K., Polo-Kantola, P., Helenius, H., Polo, O. Obstetrics and gynecology. (2000) [Pubmed]
  34. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Cano, A., Castelo-Branco, C., Tarín, J.J. Fertil. Steril. (1999) [Pubmed]
  35. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. Schiff, I., Tulchinsky, D., Cramer, D., Ryan, K.J. JAMA (1980) [Pubmed]
  36. Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N., Pasqualini, C.D. J. Natl. Cancer Inst. (1987) [Pubmed]
  37. Injectable contraception (medroxyprogesterone acetate) in rural Bangladesh. Parveen, L., Chowdhury, A.Q., Chowdhury, Z. Lancet (1977) [Pubmed]
  38. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Simons, J.P., Aaronson, N.K., Vansteenkiste, J.F., ten Velde, G.P., Muller, M.J., Drenth, B.M., Erdkamp, F.L., Cobben, E.G., Schoon, E.J., Smeets, J.B., Schouten, H.C., Demedts, M., Hillen, H.F., Blijham, G.H., Wouters, E.F. J. Clin. Oncol. (1996) [Pubmed]
WikiGenes - Universities